While an increase was recorded following growth of Lenvima (anticancer agent, product name for renal cell carcinoma indication in Europe: Kisplyx) and Fycompa (antiepileptic agent) as well as the contribution from newly added consolidated subsidiary EA Pharma Co., Ltd., the Group's revenue finished overall at down 1.6% year on year) due in part to the impact of national drug price revisions in Japan and foreign currency fluctuations.
By segment, revenue from the Group's Japan pharmaceutical business and Asia pharmaceutical business increased. Similarly, on a local currency basis, all overseas pharmaceutical businesses also achieved growth.
By product, combined revenue from all four global brands (Halaven, Lenvima, Fycompa and Belviq) soared by 14.5% year on year, despite the impact of foreign currency fluctuations.
Operating profit resulted up 13.7% year on year owing to improved performance and efficiency in operations, as well as one-off income following the acquisition of EA Pharma shares (gain from a bargain purchase) and receipt of milestone payments for progress on joint R&D projects.
Profit for the year came to down 23.3% year on year, owing to the reduced tax expenses following a transfer of shares in a U.S. subsidiary in the previous fiscal year, while profit for the year attributable to owners of the parent was down 28.4% year on year.